This “Multiple System Atrophy - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Multiple System Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting body's autonomic nervous system (involuntary action such as blood pressure or digestion) and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. MSA causes deterioration and shrinkage (atrophy) of portions of your brain (cerebellum, basal ganglia and brainstem) that regulate internal body functions, digestion and motor control. MSA, formerly known as Shy-Drager syndrome, is an alpha-synuclein-related pathology like Parkinson's disease. Alpha-synuclein accumulates in the glia in MSA, while in Parkinson's disease, it accumulates in the neurons.
Diagnosis of Multiple System Atrophy is based upon a thorough clinical examination, with various autonomic tests and imaging studies. Tests may first be performed to rule out other causes of symptoms. Positron emission tomography (PET), using fluorodeoxyglucose (FDG) to measure regional brain glucose metabolism, is being developed as a tool to differentiate between degenerative parkinsonian conditions. Blood tests and brain imaging scans, such as an MRI, can show signs that may suggest MSA.
Treatment for Multiple System Atrophy is aimed at controlling the symptoms of the disease and includes medications and lifestyle changes to help manage symptoms. Droxidopa effectively reduces neurogenic orthostatic hypotension. Fludrocortisone also may be beneficial, but patients with MSA may become resistant to the drug after six months. In addition to levodopa, other drugs used to treat Parkinson's disease may be used to treat individuals with MSA. These include dopamine agonists such as ropinirole (Requip) and pramipexole (Mirapexin) and an antiviral drug known as amantadine (Symmetrel). The drug midodrine hydrochloride (ProAmatine) has been approved by the Food and Drug Administration (FDA) for the treatment of low blood pressure sometimes associated with MSA.
This segment of the Multiple System Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Verdiperstat: Biohaven Pharmaceutical
Verdiperstat is a first-in-class, potent, selective, brain-penetrant, irreversible myeloperoxidase (MPO) enzyme inhibitor. The molecule is currently under Phase 3 clinical trial to evaluate the efficacy of verdiperstat in MSA. Verdiperstat has received Fast Track and Orphan Drug designations by the USFDA and the European Medicine Agency due to the unmet medical needs in MSA.
SBT-272: Stealth BioTherapeutics
SBT-272 is a novel peptidomimetic. SBT-272 has been shown to increase adenosine triphosphate (ATP) production and decrease levels of reactive oxygen species (ROS) in dysfunctional mitochondria in preclinical studies. The molecule is currently under preclinical studies for the treatment of multiple system atrophy (MSA).
There are approx. 20+ key companies which are developing the therapies for Multiple System Atrophy. The companies which have their Multiple System Atrophy drug candidates in the most advanced stage, i. e. phase III include, Biohaven Pharmaceutical.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multiple System Atrophy therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple System Atrophy drugs.
Geography Covered
- Global coverage
Multiple System Atrophy Understanding
Multiple System Atrophy: Overview
Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting body's autonomic nervous system (involuntary action such as blood pressure or digestion) and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. MSA causes deterioration and shrinkage (atrophy) of portions of your brain (cerebellum, basal ganglia and brainstem) that regulate internal body functions, digestion and motor control. MSA, formerly known as Shy-Drager syndrome, is an alpha-synuclein-related pathology like Parkinson's disease. Alpha-synuclein accumulates in the glia in MSA, while in Parkinson's disease, it accumulates in the neurons.
Symptoms
The symptoms of Multiple System Atrophy include:
- Rigid muscles
- Difficulty bending your arms and legs
- Slow movement (bradykinesia)
- Impaired movement and coordination
- Difficulty swallowing (dysphagia) or chewing
- Postural (orthostatic) hypotension
Diagnosis
Diagnosis of Multiple System Atrophy is based upon a thorough clinical examination, with various autonomic tests and imaging studies. Tests may first be performed to rule out other causes of symptoms. Positron emission tomography (PET), using fluorodeoxyglucose (FDG) to measure regional brain glucose metabolism, is being developed as a tool to differentiate between degenerative parkinsonian conditions. Blood tests and brain imaging scans, such as an MRI, can show signs that may suggest MSA.
Treatment
Treatment for Multiple System Atrophy is aimed at controlling the symptoms of the disease and includes medications and lifestyle changes to help manage symptoms. Droxidopa effectively reduces neurogenic orthostatic hypotension. Fludrocortisone also may be beneficial, but patients with MSA may become resistant to the drug after six months. In addition to levodopa, other drugs used to treat Parkinson's disease may be used to treat individuals with MSA. These include dopamine agonists such as ropinirole (Requip) and pramipexole (Mirapexin) and an antiviral drug known as amantadine (Symmetrel). The drug midodrine hydrochloride (ProAmatine) has been approved by the Food and Drug Administration (FDA) for the treatment of low blood pressure sometimes associated with MSA.
Multiple System Atrophy Emerging Drugs Chapters
This segment of the Multiple System Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Multiple System Atrophy Emerging Drugs
Verdiperstat: Biohaven Pharmaceutical
Verdiperstat is a first-in-class, potent, selective, brain-penetrant, irreversible myeloperoxidase (MPO) enzyme inhibitor. The molecule is currently under Phase 3 clinical trial to evaluate the efficacy of verdiperstat in MSA. Verdiperstat has received Fast Track and Orphan Drug designations by the USFDA and the European Medicine Agency due to the unmet medical needs in MSA.
SBT-272: Stealth BioTherapeutics
SBT-272 is a novel peptidomimetic. SBT-272 has been shown to increase adenosine triphosphate (ATP) production and decrease levels of reactive oxygen species (ROS) in dysfunctional mitochondria in preclinical studies. The molecule is currently under preclinical studies for the treatment of multiple system atrophy (MSA).
Multiple System Atrophy: Therapeutic Assessment
This segment of the report provides insights about the different Multiple System Atrophy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Multiple System Atrophy
There are approx. 20+ key companies which are developing the therapies for Multiple System Atrophy. The companies which have their Multiple System Atrophy drug candidates in the most advanced stage, i. e. phase III include, Biohaven Pharmaceutical.
Phases
This report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Multiple System Atrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multiple System Atrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple System Atrophy drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Multiple System Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Multiple System Atrophy.
- In August 2021, Yumanity Therapeutics and Proteostasis Therapeutics entered into a definitive merger agreement. The combined company, operate under the name Yumanity Therapeutics and will leverage a common scientific expertise in the area of protein misfolding to advance Yumanity's pipeline of innovative, disease-modifying programs for neurodegenerative diseases.
Multiple System Atrophy Report Insights
- Multiple System Atrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Multiple System Atrophy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Multiple System Atrophy drugs?
- How many Multiple System Atrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple System Atrophy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Multiple System Atrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Multiple System Atrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Biohaven Pharmaceutical
- Stealth BioTherapeutics
- Alterity Therapeutics
- Newron Pharmaceuticals
- EmeraMed
- Ionis Pharmaceuticals
- AFFiRiS
- ProMIS Neurosciences
- 1St Biotherapeutics
Key Products
- Verdiperstat
- SBT-272
- ATH 434
- Safinamide
- Emeramide
- ION-464
- Affitope-PD01A
- Affitope PD03
- PMN 300
- 1ST-104
Table of Contents
IntroductionExecutive Summary
Multiple System Atrophy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Multiple System Atrophy - Analytical Perspective
In-depth Commercial Assessment
- Multiple System Atrophy companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Multiple System Atrophy Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Verdiperstat: Biohaven Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Safinamide: Newron Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
ATH 434: Alterity Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
SBT-272: Stealth BioTherapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Multiple System Atrophy Key Companies
Multiple System Atrophy Key Products
Multiple System Atrophy- Unmet Needs
Multiple System Atrophy- Market Drivers and Barriers
Multiple System Atrophy- Future Perspectives and Conclusion
Multiple System Atrophy Analyst Views
Multiple System Atrophy Key Companies
AppendixList of Tables
Table 1 Total Products for Multiple System Atrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Multiple System Atrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Biohaven Pharmaceutical
- Stealth BioTherapeutics
- Alterity Therapeutics
- Newron Pharmaceuticals
- EmeraMed
- Ionis Pharmaceuticals
- AFFiRiS
- ProMIS Neurosciences
- 1St Biotherapeutics
